Full-Time

Senior Clinical Research Associate/Clinical Research Associate

Parexel

Parexel

10,001+ employees

End-to-end clinical trials and regulatory consulting

No salary listed

Remote in USA + 1 more

More locations: North Carolina, USA

Remote

Remote within the United States only.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Ruby

Get referred to Parexel

See people who can refer or advise you

Requirements
  • Excellent knowledge of international guidelines ICH-GCP, basic knowledge of GMP/GDP
  • Good knowledge of relevant local regulations
  • Good medical knowledge and ability to learn relevant Client Therapeutic Areas
  • Basic understanding of the drug development process
  • Good understanding of Clinical Study Management including monitoring, study drug handling and data management
  • Bachelor’s degree in related discipline, preferably in life science, or equivalent qualification (adapted to local country market needs)
  • Skills (Essential): Excellent attention to detail; Good written and verbal communication skills; Good collaboration and interpersonal skills; Good negotiation skills; Proficient in written and spoken English language required; Fluency in local language(s) required
  • Education: Bachelor’s degree in related discipline, preferably in life science, or equivalent qualification (adapted to local country market needs)
  • Other: Ability to travel nationally/internationally as Required; Valid driving license per country requirements, as applicable
  • Knowledge and Experience (Essential): Excellent knowledge of international guidelines ICH-GCP, basic knowledge of GMP/GDP; Good knowledge of relevant local regulations; Good medical knowledge and ability to learn relevant Client Therapeutic Areas; Basic understanding of the drug development process; Good understanding of Clinical Study Management including monitoring, study drug handling and data management
Responsibilities
  • Contributes to the selection of potential investigators.
  • In some countries, as required, CRAs are accountable for study start-up and regulatory maintenance. Tasks may include Site Qualification Visits, collection, preparation, review and tracking of documents for the application process; submission of proper application/documents to EC/IRB and to Regulatory Authorities for start-up and for the duration of the study.
  • Trains, supports, and advises Investigators and site staff in study related matters, including Risk Based Quality Management (RbQM) principles.
  • Confirms that site staff have completed and documented the required training appropriately, including ICH-GCP training, prior to and for the duration of the study. Ensures the sites are inspection ready at all times.
  • Actively participates in Local Study Team (LST) meetings.
  • Contributes to National Investigators meetings, as applicable.
  • Initiates, monitors, and closes study sites in compliance with Client Procedural Documents. Shares information on patient recruitment and study site progress (site quality/performance) within the LST.
  • Drives performance at the sites. Proactively identifies and ensures timely resolution to study-related issues and escalates them as appropriate.
  • Updates CTMS and other systems with data from study sites as per required timelines.
  • Manages study supplies (Investigator Site File (ISF), etc.), drug supplies and drug accountability at study site. Prepares study drug for destruction, if applicable.
  • Performs monitoring visits (remote and onsite), as well as remote data checks, in accordance with the timelines specified in the study specific Monitoring Plan. If required, determines, and discusses with LSAD the correct timing and type of visits.
  • Performs Source Data Review (SDR), Case Report Form (CRF) review and Source Data Verification (SDV), in accordance with the Monitoring Plan.
  • Performs regular Site Quality Risk Assessments and adapts monitoring intensity accordingly during the study.
  • Ensures data query resolution in a timely manner.
  • Works with data management to ensure robust quality of the collected study data.
  • Ensures accurate and timely reporting of Serious Adverse Events and their follow ups.
  • Prepares and finalizes monitoring visit reports in CTMS and provides timely feedback to the Principal Investigator, including follow-up letter, within required timelines and in line with Client SOP.
  • Follows up on outstanding actions with study sites to ensure resolution in a timely manner.
  • Follows quality issue processes by escalating systematic or serious quality issues, data privacy breaches, Clinical Study Protocol (CSP) or ICH-GCP compliance issues to Local Management and/or Clinical Quality Management (CQM) as required.
  • Assists site in maintaining inspection ready ISF.
  • Prepares for and collaborates with the activities associated with audits and regulatory inspections in liaison with LSAD and Clinical Quality Associate Director (CQAD).
  • Ensures timely collection/uploading of essential documents into the eTMF in accordance with ICH-GCP, Client SOPs and local requirements. Supports/participates in regular QC checks performed by LSAD or delegate.
  • Ensures that all study documents under their responsibility (i.e., site documents, relevant communications, etc.) are available and ready for final archiving and completion of local part of the eTMF.
  • Provides feedback on any research related information including sites/investigators/competing studies that might be useful for the local market.
  • Collaborates with local Medical Science Liaisons (MSLs) as directed by LSAD or line manager.
Desired Qualifications
  • Ability to work in an environment of remote collaborators
  • Manages change with a positive approach for self, team, and the business. Sees change as an opportunity to improve performance and add value to the business
  • Ability to look for and champion more efficient and effective methods/processes of delivering quality clinical trials with reduced budget and in less time
  • Good analytical and problem-solving skills
  • Demonstrates ability to prioritize and manage multiple tasks with conflicting deadlines
  • Ability to understand the impact of technology on projects and to use and develop computer skills while making appropriate use of systems/software in an e-enabled environment
  • Team oriented and flexible; ability to respond quickly to shifting demands and opportunities
  • Familiar with risk-based monitoring approach including remote monitoring
  • Good cultural awareness

Parexel provides end-to-end clinical development services for pharmaceutical, biotechnology, and medical device clients from Phase I to Phase IV. Its offerings include clinical trial management, regulatory consulting, and biostatistical analysis to support the design, execution, and analysis of clinical studies. The company operates as a CRO, partnering with sponsors to manage trials, ensure regulatory compliance, and generate robust data for drug development. What sets Parexel apart is its breadth of services across the trial lifecycle, emphasis on quality and reliability, and industry recognition, along with a focus on patient-centric approaches and leadership in gender partnership. The company’s goal is to help clients bring new therapies to market efficiently and safely by delivering high-quality, compliant trial outcomes and data that support regulatory submissions.

Company Size

10,001+

Company Stage

Acquired

Total Funding

$8.5B

Headquarters

Durham, North Carolina

Founded

1982

Get referred to Parexel

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • ParexelAI launched May 18, 2026, with 50% faster site selection timelines.
  • Vitrana acquisition on April 29, 2026 strengthens pharmacovigilance and compliance workflows.
  • ASCO, EHA, and DIA 2026 visibility reinforces Parexel’s oncology and hematology credibility.

What critics are saying

  • Weave Bio and sponsor-built AI software compress Parexel’s regulatory and safety margins by 2027.
  • EQT and Goldman can force margin discipline, cutting headcount if growth softens.
  • If AI-enabled sponsors internalize trials, Parexel risks becoming a commoditized execution layer.

What makes Parexel unique

  • Parexel combines full-service CRO delivery with proprietary AI and regulatory automation.
  • Its 2026 Parexel Biotech Incubator deepens early-stage biotech origination in Raleigh.
  • Parexel’s patient-centric site alliances and real-world research create sticky sponsor relationships.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

2%

1 year growth

2%

2 year growth

5%
Alabama Cultural Times
Jul 27th, 2026
Parexel recognized as a World's Top Disability Inclusive Business by the Disability Index(R) from disability:in.

Parexel recognized as a World's Top Disability Inclusive Business by the Disability Index(R) from disability:in. Reflecting company's commitment to advancing inclusion and accessibility across its global workforce and in its clinical trials. RALEIGH, N.C., July 27, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced its recognition as a World's Top Disability Inclusive Business based on its high performance on the Disability Index(R), the leading global benchmark for disability inclusion in business. "We are proud to be recognized as a World's Top Disability Inclusive Business, an achievement that underscores our continued commitment to fostering a culture where every colleague feels valued, respected and supported," said Peyton Howell, Chief Executive Officer. "This commitment is also integral to how we operate and deliver for patients. Bringing together diverse experiences and perspectives helps us design more patient-focused clinical research and develop solutions that reduce barriers to trial access and participation. Ultimately, we believe this commitment and approach support our mission to accelerate the delivery of life-changing treatments to patients around the world." Parexel's recognition reflects a comprehensive, company-wide commitment to creating an environment where colleagues and patients - regardless of physical ability or other differences - can participate and thrive in clinical research. This includes: * Leadership commitment, with inclusion embedded into governance, strategy and executive engagement * Inclusive culture and community, supported by Parexel's core values and ParAbility, an executive sponsored Business Resource Group dedicated to advancing accessibility, inclusion and support for all colleagues and patients * Innovative clinical research solutions that lower barriers to clinical trial participation for people with disabilities and reflect diverse patient population needs * Fairness in hiring and professional development, with accessible recruitment, accommodations and continuous learning opportunities * Accessible environments, including ongoing efforts to ensure physical and digital accessibility across the workplace and foster a culture of trust where colleagues feel comfortable disclosing disabilities and seeking support when needed * Comprehensive support and benefits, designed to promote well-being and equitable access for all colleagues * Strategic supplier partnerships, advancing opportunities for disability-owned businesses across the value chain The Disability Index is trusted by over 70% of the Fortune 100 and nearly half of the Fortune 500 and provides companies with data-driven insights to assess performance, identify opportunities and drive continuous improvement over time. The Disability Index uses a structured, data-driven methodology that enables consistent benchmarking across companies and industries. Companies scoring at the highest proficiency levels earn recognition as World's Top Disability Inclusive Businesses, signaling leadership and progress to employees, customers and partners. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives Alabama Cultural Times forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). Alabama Cultural Times continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow Alabama Cultural Times on LinkedIn, X, Facebook and Instagram. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Alabama Cultural Times do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Africa Daily Journal
Jun 22nd, 2026
Parexel launches Parexel Biotech Incubator to connect early-stage innovation with clinical development expertise.

Parexel launches Parexel Biotech Incubator to connect early-stage innovation with clinical development expertise. Initiative creates new resource to support and accelerate early-stage therapeutics companies Parexel forms inaugural partnership with Durham-based Cape Fear BioCapital to connect incubator to a seed-stage venture partner RALEIGH, N.C., June 22, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced the launch of the Parexel Biotech Incubator, a new initiative anchored at the company's North Hills Innovation District global headquarters in Raleigh that connects early-stage therapeutics companies with the clinical and regulatory expertise they need to advance their programs. The incubator launches alongside an inaugural partnership with Cape Fear BioCapital, a Durham-based seed-stage venture capital firm, and builds on Parexel's growing commitment to supporting early-stage innovation in collaboration with the venture community. The Parexel Biotech Incubator is designed to support emerging therapeutics companies at a stage when development strategy is still taking shape. Participating companies will have access to Parexel's clinical and regulatory expertise - including guidance on development planning, regulatory strategy and clinical trial design - alongside shared physical space that puts them in direct proximity to Parexel's Raleigh-based team and provides a collaborative home rather than resources and investment alone. "Reaching innovators at the earliest stages of their development journey, before clinical programs are formally structured, is where we can have the greatest impact. That is exactly what this initiative is designed to do," said Peyton Howell, Chief Executive Officer of Parexel. "The incubator reflects the evolution of our support for the biotech community, connecting seed-stage investment to clinical development expertise at the stage when it matters most. It builds on our broader commitment to investing in early-stage innovation alongside leading venture firms, and our inaugural partnership with Cape Fear BioCapital deepens our roots in one of the most dynamic life sciences ecosystems in the country." The incubator builds on Parexel's broader commitment to investing in and fostering early-stage innovation alongside leading venture capital firms. Parexel has established collaborative relationships with leading venture firms as part of its strategy to advance and accelerate the next generation of therapeutics companies. The partnership with Cape Fear BioCapital is designed to address a gap that early-stage therapeutics companies frequently face, where seed-stage investment and clinical development expertise rarely come together at the right time. Cape Fear BioCapital focuses on advancing companies from early discovery through IND-readiness, and the alliance creates a direct connection between its portfolio companies and Parexel's clinical and regulatory expertise at the stage when development decisions carry the most weight. "The Parexel Biotech Incubator represents the next stage in Parexel Biotech's evolution and extends our long-standing commitment to the biotech community," said Jim Anthony, Chief Commercial Officer and President, Parexel Biotech. "By bringing our clinical and regulatory expertise to emerging innovators earlier in their development journeys, we can help companies make smarter development decisions, build stronger plans and position promising programs for lasting progress." North Carolina ranks seventh in the United States for life sciences employment, with more than 103,000 workers across nearly 6,700 establishments statewide. Anchored by Research Triangle Park, one of the world's largest research parks, the state is also home to leading research institutions including Duke University, the University of North Carolina at Chapel Hill and NC State University. Cape Fear BioCapital's deep ties to all three institutions reinforce the regional research pipeline helping shape North Carolina's next generation of therapeutics companies. "North Carolina has the scientific substrate, talent, and entrepreneurial ambition to build on our strong base of therapeutics innovation," said Dave Ousterout, General Partner at Cape Fear BioCapital. "Working together with Parexel, we are dedicated to supporting emerging companies and connecting them with development expertise at a stage when strategic guidance can make a meaningful difference. Our partnership reflects a shared commitment to strengthening the support and capital available to innovators across the state." Since establishing its Durham location in 2014, Parexel has continued to invest in North Carolina, expanding its presence in 2019 and opening its global headquarters in Raleigh's North Hills Innovation District in 2025. Launched in 2019, Parexel Biotech is the company's dedicated business unit serving emerging biopharmaceutical innovators and reflects Parexel's continued focus on supporting biotech companies as they navigate key development milestones. About the Parexel Biotech Incubator The Parexel Biotech Incubator gives early-stage companies direct access to Parexel's clinical and regulatory expertise, reflecting Parexel's commitment to engaging biotech innovators earlier and building relationships that support future development needs. It is anchored at Parexel's North Hills Innovation District global headquarters in Raleigh, supporting emerging therapeutics companies wherever they are based. About Cape Fear BioCapital Cape Fear BioCapital is a seed-stage venture capital firm dedicated to investing in and building early-stage therapeutics companies in North Carolina. Founded in 2024 by Ed Field, Jimmy Melton and Dave Ousterout, the firm works to advance portfolio companies from early discovery through IND-readiness, filling a critical gap in the state's early-stage life sciences funding landscape. Cape Fear BioCapital is anchored by Moore Strategic Ventures and maintains deep ties to Duke University, the University of North Carolina at Chapel Hill and NC State University. For more information, visit capefearbiocap.com. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives Africa Daily Journal forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). Africa Daily Journal continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow Africa Daily Journal on LinkedIn, X, Facebook and Instagram. Heather Zoumas-Lubeski +1 (984) 218-5539 [email protected] Danaka Williams +1 (984) 298-4207 [email protected] Parexel launches Parexel Biotech Incubator. Initiative creates new resource to support and accelerate early-stage therapeutics companies. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Africa Daily Journal do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

News Break Middle East
Jun 11th, 2026
Parexel to highlight expertise across eight thought leadership sessions at 2026 DIA Global Annual Meeting.

Parexel to highlight expertise across eight thought leadership sessions at 2026 DIA Global Annual Meeting. Presentations, panels and moderated discussions across the four-day conference will span proven AI applications across the clinical trial lifecycle, real world evidence, risk-based quality management and patient-centered research. RALEIGH, N.C., June 11, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, will present during eight sessions at the 2026 Drug Information Association (DIA) Global Annual Meeting, taking place June 14-18, 2026, in Philadelphia. Company executives and subject matter experts will present, moderate and participate in panels about proven AI applications across the clinical trial lifecycle, real world evidence, risk-based quality management and patient-centered research. Sessions featuring Parexel representatives are scheduled throughout the conference: * #425 IT: "The Connected Submission - How AI, Automation, and Intelligence are Changing the Regulatory Ecosystem" * Speaker: Katie Connelly, Senior Vice President, Global Head of Regulatory Affairs * Date and time: Monday, June 15 from 1:05 p.m. - 1:35 p.m. * #503 IT: "Human-Centered AI - A Dual-Layer Model for Clinical Research Excellence" * Speaker: Aneiss Ghodsi, Head of AI Engineering * Date and time: Tuesday, June 16 from 9:15 a.m. - 9:45 a.m. * #515: "Leveraging Federated AI and Open Data to Transform Oncology Research and Development" * Speaker: Stacy Hurt, Chief Patient Officer * Date and time: Tuesday, June 16 from 10:15 a.m. - 11:30 a.m. * #519: "Patient Registries: Basket Trial or Basket Case?" * Panelist: Mike D'Ambrosio, Senior Vice President and Global Head of Real World Research * Date and time: Tuesday, June 16 from 10:15 a.m. - 11:30 a.m. * #521.1: "Patient Appreciation Session: Celebrating the Patient Voice" * Speaker: Stacy Hurt, Chief Patient Officer * Date and time: Tuesday, June 16 from 11:45 a.m. - 12:30 p.m. * #637: "Destigmatizing 483 Observations" * Panelist: Cris McDavid, Senior Director of Clinical Operations * Date and time: Wednesday, June 17 from 1:45 p.m. - 2:45 p.m. * #647: "Not Can, but Should: How do we WANT AI/ML to Transform Clinical Development?" * Panelist: Tala Fakhouri, Chief AI & Regulatory Strategy Officer * Date and time: Wednesday, June 17 from 4:00 p.m. - 5:00 p.m. * #701: "No Report Left Behind: Human-Centered Safety Reporting" * Moderator: Stacy Hurt, Chief Patient Officer * Date and time: Thursday, June 18 from 8:00 a.m. - 9:00 a.m. "DIA is a premier forum for advancing clinical development innovation, and Parexel is proud to showcase how AI, clinical trial innovation and human-centered approaches are transforming the industry," said Keri Mattox, Chief Business & Strategy Officer, Parexel. "Our participation reflects Parexel's commitment to research and thought leadership, and our dedication to accelerating the delivery of safe, effective therapies to patients worldwide." DIA is a global, multidisciplinary organization bringing together professionals across the entire spectrum of the life sciences industry. DIA serves as a neutral platform for knowledge exchange, fostering innovation and advancing global health through educational resources, conferences and collaboration among stakeholders. Parexel will exhibit at Booth #1503 throughout the meeting. For more information about Parexel's presence at DIA 2026 or to schedule a meeting with Parexel experts, visit Parexel Events. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, its 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Its proven track record spans 40+ years and drives News Break Middle East forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Its insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). News Break Middle East continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow News Break Middle East on LinkedIn, X, Facebook and Instagram. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. News Break Middle East do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

GlobeNewswire
Jun 10th, 2026
Parexel to showcase seven research posters and debut new Hematology Playbook at the European Hematology Association Congress 2026.

Parexel to showcase seven research posters and debut new Hematology Playbook at the European Hematology Association Congress 2026. Five in-person poster presentations and two virtual posters highlight Parexel's thought leadership in real-world evidence, comparative outcomes and regulatory insights across hematologic diseases "At the Turning Point: Shaping the Future of Hematology" playbook offers strategic guidance for hematology drug developers to accelerate their programs and bring new products to patients RALEIGH, N.C., June 10, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced its experts will present seven research posters during the European Hematology Association (EHA) 2026 Congress, June 11-14 in Stockholm, Sweden. Parexel's presence at EHA 2026 will also mark the launch of At the Turning Point: Shaping the Future of Hematology, a thought leadership resource grounded in the company's expertise and insights from 250 hematology programs across nearly 70 countries over the past five years. Poster Presentations Parexel researchers will present seven posters during EHA 2026, including five in person and two available online. Poster abstracts are embargoed until June 11 at 8 a.m. CEST: In-Person Presentations (all times are CEST): * "Comparative Real-World Overall Survival in Diffuse Large B-Cell Lymphoma: CAR T-Cell Therapies Versus Bispecific Antibodies" * First author: Vladimir Otasevic, M.D., Ph.D., Associate Medical Director * Date and time: Friday, June 12 from 6:45 p.m. - 7:45 p.m. * "ICANS After CAR-T Therapy: Persistent Cognitive but Not Psychiatric Risk - A Propensity Score-Matched Analysis" * First author: Heidi Cho, M.D., Vice President, Franchise Head and Global Therapeutic Area Head, Hematology * Date and time: Saturday, June 13 from 6:45 p.m. - 7:45 p.m. * "Impact of Autologous Stem Cell Transplantation Following Quadruplet Therapy (Dara-VRd) on Survival Outcomes in Multiple Myeloma: A Real-World Data Analysis" * First author: Lanzhu Yue, M.D., Ph.D., Medical Director, Therapeutic Area Head of Lymphoma and Non-Malignant Hematology * Date and time: Friday, June 12 from 6:45 p.m. - 7:45 p.m. * "Real-World Outcomes of Sickle Cell Disease Patients Transitioning From Pediatric to Adult Care: Impact on Acute Care Utilization" * First author: Heidi Cho, M.D., Vice President, Franchise Head and Global Therapeutic Area Head, Hematology * Date and time: Friday, June 12 from 6:45 p.m. - 7:45 p.m. * "Risk of Bleeding in Mantle Cell Lymphoma Patients Treated with Covalent Bruton Tyrosine Kinase Inhibitors and Contemporary Anticoagulant or Antiplatelet Agents: Real-World Data Insights" * First author: Vladimir Otasevic, M.D., Ph.D., Associate Medical Director * Date and time: Saturday, June 13 from 6:45 p.m. - 7:45 p.m. Available Online: "Emerging therapies in hematology are advancing at an extraordinary pace, creating new opportunities to improve patient outcomes through longer remissions, more effective disease management and innovative treatment approaches," said Heidi Cho, M.D., Vice President, Franchise Head and Global Therapeutic Area Head, Hematology at Parexel, who will lead the company's on-site activities at the meeting. "Our research presentations and new hematology playbook reflect the depth of experience Parexel has gained across hundreds of global hematology studies. Our experiences provide actionable insights to help sponsors navigate complexity, make critical development decisions with greater confidence and help bring transformative therapies to patients faster." The European Hematology Association is the leading professional organization dedicated to the research, diagnosis and treatment of blood diseases, bringing together thousands of clinicians, scientists and industry professionals each year. Launch of the Hematology Playbook Authored by Parexel subject matter experts, At the Turning Point: Shaping the Future of Hematology addresses trial design innovation, patient-centric development strategies, navigation of the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and National Medicinal Products Administration (NMPA) regulatory landscape, operationalization of complex hematology trials, and the integration of real-world evidence from the start of development. The resource is written for hematology drug developers, including biotech and pharmaceutical sponsors approaching first-in-human studies, preparing for Phase III studies, and managing multi-regional development. Key Findings * Five-year relative survival rates for blood cancers have climbed significantly over the past three decades, rising from 48% to 68% for leukemia and 32% to 62% for myeloma. As a result, the pool of patients eligible for clinical trials has shifted, intensifying competition for enrollment across hematology studies. * Patient navigation deployment drove a 29% decrease in screen fail rate across a Parexel-supported hematology study, with 100% of sites opting into navigator support. * Gene therapies for sickle cell disease and hemophilia approved between 2023 and 2025 have fallen short of projected commercial uptake, a pattern the playbook traces to poorly defined patient profiles during protocol design. * China's investigator-initiated trial pathway can be approximately two years faster and substantially less costly than other traditional IND routes, positioning the country as a strategic accelerator for first-in-human hematology studies. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). We continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.

GlobeNewswire
May 28th, 2026
Parexel to present real-world oncology Research and launch new patient-focused campaign at ASCO 2026.

Parexel to present real-world oncology Research and launch new patient-focused campaign at ASCO 2026. Two virtual posters accepted exploring rejections in oncology marketing applications and real-world pulmonary safety of T-DXd in HER2-positive metastatic breast cancer From Insights to Life campaign reinforces Parexel's commitment and position as the leading patient-first clinical development partner RALEIGH, N.C., May 28, 2026 (GLOBE NEWSWIRE) - Parexel, a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry, today announced two virtual research posters accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June 2, in Chicago. The research examines critical challenges in oncology drug development and real-world safety outcomes for a HER2-targeted therapy, grounding Parexel's ASCO presence in the evidence that advances cancer care. The company also unveiled From Insights to Life, a new patient-focused creative campaign reflecting Parexel's commitment to helping sponsors advance their programs so patients can return to what matters most to them. Virtual Poster Presentations As part of ASCO 2026, Parexel is presenting two virtual research posters, one analyzing common deficiencies in oncology marketing applications that lead to FDA rejections and another focused on the pulmonary safety profile of trastuzumab deruxtecan (T-DXd) in HER2-positive metastatic breast cancer. Parexel's oncology experience over the past five years spans more than 560 clinical studies, more than 104,000 patients and more than 26,000 sites across more than 50 countries. Over that same period, Parexel Biotech delivered the data supporting six U.S. Food and Drug Administration (FDA) and three European Medicines Agency (EMA) new solid-tumor oncology drug approvals. "ASCO is where the oncology community comes together to advance science that matters for patients, and Parexel's presence reflects that same commitment," said Jozsef Palatka, M.D., Senior Vice President and Global Therapeutic Head of Oncology at Parexel, who will lead the company's on-site activities at the meeting. "The research we are presenting exemplifies the rigor we bring to every program. Translating real-world evidence into confident clinical development decisions is how we help sponsors advance therapies forward for the patients who need them." Joining Dr. Palatka on-site will be Charlotte Moser, Chief Medical Officer, Jim Anthony, Chief Commercial Officer and President, Parexel Biotech, Stacy Hurt, Chief Patient Officer, Mike D'Ambrosio, Senior Vice President and Global Head of Real World Research, and members of Parexel's medical, commercial and marketing teams. From Insights to Life The company also announced the launch of From Insights to Life, a new patient-focused creative campaign centered on real people, representing different disease states and demographics, navigating the space between a medical diagnosis and daily living. Inspired by patient experiences and driven by a sense of purpose, the campaign reaffirms Parexel's commitment to delivering clinical trials that support patients in continuing to live the lives they love. "What patients want most is to feel genuinely seen by the people working on their behalf, recognized for the full life they are striving to return to," said Stacy Hurt, Chief Patient Officer at Parexel. "At Parexel, truly listening to patients is the principle that guides every decision we make, every trial we design and every partnership we form. From Insights to Life captures something I have felt throughout my relationship with Parexel - when patients are placed at the center of everything we do, it fundamentally changes what is possible. It's the difference between advancing science and creating solutions that genuinely change people's lives." From Insights to Life builds on the foundation of Parexel's award-winning Insights Generation Engine campaign, which was recognized by PR Week's 2026 Corporate Healthcare Campaign Award. Where Insights Generation Engine celebrates the expertise of Parexel's colleagues, From Insights to Life extends that commitment outward to the patients who Parexel serves. The campaign will roll out throughout 2026 with additional original compositions unveiled across Parexel's website, digital and social channels, and activations at milestone biopharmaceutical industry events, such as the American Diabetes Association and the World Orphan Drug Congress. Each new patient-focused campaign image reinforces Parexel's mission - translating insight into meaningful impact across the clinical development journey and accelerating life-changing medicines to patients. About Parexel Parexel is a leading global clinical development partner providing insights-driven Clinical and Consulting solutions to the world's life sciences industry. Leveraging deep local knowledge and a global breadth of clinical, regulatory and therapeutic expertise, our 22,000+ global employees work in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind - broadening access and making clinical research a care option for anyone, anywhere. Our proven track record spans 40+ years and drives us forward, advancing clinical research in healthcare's most complex areas while harnessing innovation to drive efficiencies across every phase of the clinical development process. Our insights-driven approach, proven delivery and trusted execution are accelerating the delivery of life-changing treatments to patients - With Heart(R). We continue to earn recognition industrywide, including the 2025 Scrip Award for "Best Contract Research Organization - Full-Service Provider," the 2024 Fierce Biotech CRO Award for "Innovative Approaches to Patient-Centric Research" and the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships. For more information, visit parexel.com and follow us on LinkedIn, X, Facebook and Instagram.